P C Adamson

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Stress lysis in childhood leukemia
    Peter C Adamson
    Division of Clinical Pharmacology and Therapeutics and Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 50:137-9. 2008
  2. ncbi request reprint The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias
    Peter C Adamson
    Division of Clinical Pharmacology and Therapeutics, The Children s Hospital of Philadelphia, ARC 916, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA
    Pediatr Cardiol 27:420-7. 2006
  3. ncbi request reprint New approaches to drug development in pediatric oncology
    Peter C Adamson
    The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cancer J 11:324-30. 2005
  4. ncbi request reprint Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101
    P C Adamson
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Cancer Chemother Pharmacol 53:482-8. 2004
  5. ncbi request reprint A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study
    Peter C Adamson
    The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Pediatr Blood Cancer 49:661-5. 2007
  6. ncbi request reprint Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial
    S M Blaney
    Pediatric Branch, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 15:1538-43. 1997
  7. ncbi request reprint Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer
    P C Adamson
    Pediatric Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 15:3330-7. 1997
  8. ncbi request reprint A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study
    P C Adamson
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 7:3034-9. 2001
  9. ncbi request reprint Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid
    B C Widemann
    Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    J Pharmacol Exp Ther 294:894-901. 2000
  10. ncbi request reprint Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates
    W Salzer
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Cancer Chemother Pharmacol 48:235-40. 2001

Research Grants

Detail Information

Publications73

  1. ncbi request reprint Stress lysis in childhood leukemia
    Peter C Adamson
    Division of Clinical Pharmacology and Therapeutics and Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 50:137-9. 2008
    ..002). The basis for this often-observed phenomenon appears to be that leukemic cells rapidly lyse in response to the stress-induced release of endogenous corticosteroids...
  2. ncbi request reprint The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias
    Peter C Adamson
    Division of Clinical Pharmacology and Therapeutics, The Children s Hospital of Philadelphia, ARC 916, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA
    Pediatr Cardiol 27:420-7. 2006
    ..Seventeen of the subjects (63%) converted to normal sinus rhythm in an average of 2 min (range 0-5 min). The pharmacokinetics of esmolol and its efficacy in terminating SVT in children is similar to that observed in adults...
  3. ncbi request reprint New approaches to drug development in pediatric oncology
    Peter C Adamson
    The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cancer J 11:324-30. 2005
    ..The goal of these initiatives is to improve the overall outcome for childhood cancer while minimizing the short and long-term sequelae associated with current treatment strategies...
  4. ncbi request reprint Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101
    P C Adamson
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Cancer Chemother Pharmacol 53:482-8. 2004
    ....
  5. ncbi request reprint A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study
    Peter C Adamson
    The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Pediatr Blood Cancer 49:661-5. 2007
    ....
  6. ncbi request reprint Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial
    S M Blaney
    Pediatric Branch, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 15:1538-43. 1997
    ..A phase I trial of docetaxel was performed to determine the maximum-tolerated dose (MTD), the dose-limiting toxicities, and the incidence and severity of other toxicities in children with refractory solid tumors...
  7. ncbi request reprint Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer
    P C Adamson
    Pediatric Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 15:3330-7. 1997
    ....
  8. ncbi request reprint A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study
    P C Adamson
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 7:3034-9. 2001
    ..o. tid in pediatric patients with refractory cancer and to study the pharmacokinetics of 9cRA and determine whether systemic drug exposure changes with chronic dosing...
  9. ncbi request reprint Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid
    B C Widemann
    Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    J Pharmacol Exp Ther 294:894-901. 2000
    ..In nonhuman primates metabolism of DAMPA is a major route of DAMPA elimination, and metabolism underlies the more rapid elimination of DAMPA versus MTX in patients with MTX-induced renal dysfunction after administration of CPDG(2)...
  10. ncbi request reprint Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates
    W Salzer
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Cancer Chemother Pharmacol 48:235-40. 2001
    ....
  11. ncbi request reprint The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model
    B C Widemann
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Cancer Chemother Pharmacol 44:439-43. 1999
    ..Intracellularly, raltitrexed is polyglutamated to its active form which can be retained in cells for prolonged periods. The pharmacokinetics of raltitrexed in plasma and cerebrospinal fluid (CSF) were studied in a nonhuman primate model...
  12. ncbi request reprint Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates
    E Fox
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 47:41-4. 2001
    ..No hypericin was detected in the CSF of any animal (lower limit of detection 0.1 microM); the CSF penetration is therefore less than 1%. A severe dose-limiting photosensitivity skin rash was seen at the 5 mg/kg dose level...
  13. ncbi request reprint Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors
    K E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 18:1020-6. 2000
    ..We measured the relative tumor concentrations of these biochemical markers in children with recurrent brain tumors and evaluated their potential prognostic significance...
  14. ncbi request reprint Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study
    E S Lowe
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10, Room 13C103, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 47:199-205. 2001
    ....
  15. pmc Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium
    Richard Aplenc
    MSCE, The Children s Hospital of Philadelphia, Pediatric Oncology Stem Cell Transplant, Philadelphia, PA 19104 4318, USA
    J Clin Oncol 29:839-44. 2011
    ..CONCLUSION Overall, drug disposition and tolerability of dasatinib were similar to those observed in adult patients...
  16. ncbi request reprint A tale of three princes and two physicists--the importance of "why?"
    Giulio J D'Angio
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
    Med Pediatr Oncol 41:132-5. 2003
  17. pmc Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants
    Kelly C Wade
    Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Pediatr Infect Dis J 28:717-23. 2009
    ..Fluconazole is increasingly used to prevent and treat invasive candidiasis in infants. Dosing guidance remains empiric and variable because limited pharmacokinetic data exist...
  18. doi request reprint Imaging in early phase childhood cancer trials
    Peter C Adamson
    The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Pediatr Radiol 39:S38-41. 2009
    ..Development and application of novel imaging modalities for children with cancer can serve to streamline development of molecularly targeted agents...
  19. ncbi request reprint Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study
    P C Adamson
    Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892
    Cancer Res 51:6079-83. 1991
    ..These results indicate that the IT administration of 6-MP is feasible, is not associated with significant toxicity, and has definite activity in patients with refractory meningeal leukemia...
  20. ncbi request reprint Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors
    K E Warren
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892 1928, USA
    Cancer Chemother Pharmacol 48:275-82. 2001
    ..To determine the maximum tolerated dose (MTD), the incidence and severity of toxicities, and the pharmacokinetics of lobradimil administered intravenously over 10 min in combination with carboplatin in children with refractory brain tumors...
  21. ncbi request reprint Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader
    B C Widemann
    Address correspondence to this author at Pediatric Oncology Branch, National Cancer Institute, Bldg 10, Rm 13N240, 10 Center Dr, Bethesda, MD 20892 1928 USA
    Clin Chem 45:223-8. 1999
    ..Because of its greater specificity, the DHFR enzyme inhibition assay may be useful when DAMPA is present in plasma samples and HPLC is not available...
  22. ncbi request reprint Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations
    J A Lawrence
    Medicine Branch, and Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Oncol 19:2754-63. 2001
    ..CONCLUSION: The combination of tamoxifen and alitretinoin is well tolerated and has antitumor activity in metastatic breast cancer. The recommended phase II dose is 70 mg/m2/d with 20 mg/d tamoxifen...
  23. doi request reprint The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial
    Sarah Tabbutt
    Cardiac Intensive Care Unit, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Thorac Cardiovasc Surg 136:321-8. 2008
    ..We report the first prospective multi-institutional trial addressing the safety and efficacy of esmolol after repair of coarctation of the aorta in infants and children...
  24. ncbi request reprint The plasma pharmacokinetics and cerebral spinal fluid penetration of intravenous topiramate in newborn pigs
    Jeffrey L Galinkin
    Department of Anesthesiology and Critical Care Medicine, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Biopharm Drug Dispos 25:265-71. 2004
    ..The plasma pharmacokinetics, cerebrospinal fluid (CSF) penetration and pharmacodynamics of intravenous topiramate were studied in an established piglet model of hypoxia-ischemia...
  25. pmc Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncolo
    R Aplenc
    Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Pharmacoepidemiol Drug Saf 21:37-43. 2012
    ....
  26. ncbi request reprint Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction
    B C Widemann
    Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    J Clin Oncol 15:2125-34. 1997
    ..The pharmacologic and clinical outcome of CPDG2 rescue administered with thymidine and leucovorin in 20 patients is presented here...
  27. ncbi request reprint Population pharmacokinetic investigation of actinomycin-D in children and young adults
    John T Mondick
    Division of Clinical Pharmacology and Therapeutics, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    J Clin Pharmacol 48:35-42. 2008
    ..Relationships between pharmacokinetics and toxicity will be examined in future prospective studies in which children less than 1 year old will be enrolled...
  28. pmc Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Blood 111:566-73. 2008
    ..15 mg/kg per day. The response rate in children with relapsed APL is similar to the response rate in adults. This trial was registered as #NCT00020111 at www.ClinicalTrials.gov...
  29. doi request reprint Shortening the timeline of pediatric phase I trials: the rolling six design
    Jeffrey M Skolnik
    Children s Hospital of Philadelphia, Abramson Research Center 916, 3615 Civic Center Blvd, Philadelphia, PA 19104 4318, USA
    J Clin Oncol 26:190-5. 2008
    ..To shorten the study conduct timeline of pediatric phase I oncology trials by employing a novel trial design...
  30. doi request reprint A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
    Elizabeth Fox
    Authors Affiliations Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:1111-5. 2008
    ..To determine the toxicity profile, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) of ABT-751 administered orally once daily for 21 days, repeated every 28 days in a pediatric population...
  31. doi request reprint Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation
    Blaine W Robinson
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Br J Haematol 141:827-39. 2008
    ..The abundant BCL-2 affords a molecular target in leukaemias with t(4;11). G3139 exhibits preclinical activity and synergy with select cytotoxic agents in RS4:11 and MV4-11 cells, and these effects occur through apoptosis...
  32. doi request reprint Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors
    Elizabeth Fox
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892 1101, USA
    Cancer Chemother Pharmacol 66:737-43. 2010
    ..To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes...
  33. pmc A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma
    Emily Lipsitz
    Division of Clinical Pharmacology and Therapeutics, The Children s Hospital of Philadelphia, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 878:2369-73. 2010
    ..The analytical method showed excellent sensitivity, precision, and accuracy. This method is robust and is being successfully employed in a Children's Oncology Group Phase 1 Consortium study of MLN8237 in children with cancer...
  34. pmc Population pharmacokinetics of dexmedetomidine in infants after open heart surgery
    Felice Su
    Division of Clinical Pharmacology and Therapeutics, Abramson Research Center, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Anesth Analg 110:1383-92. 2010
    ..Only limited pharmacokinetic data are available for pediatric patients. The primary aim of this study was to determine the pharmacokinetics of dexmedetomidine in infants after open heart surgery...
  35. ncbi request reprint Liquid chromatography-electrospray mass spectrometry (LC-MS) method for determination of esmolol concentration in human plasma
    Athena F Zuppa
    Division of Clinical Pharmacology and Therapeutics, Department of Pediatrics, The Children s Hospital of Philadelphia, Abramson Research Center, Suite 907, 3615 Civic Center Blvd, Philadelphia, PA 19104 4318, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 796:293-301. 2003
    ..2 and 282.2. The assay is linear between 2 and 1000 ng/ml. The intra-day and inter-day coefficients of variation are less than 8 and 10%, respectively...
  36. ncbi request reprint Pediatric phase I trials in oncology: an analysis of study conduct efficiency
    Debra P Lee
    Division of Clinical Pharmacology and Therapeutics, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Clin Oncol 23:8431-41. 2005
    ..To determine the efficacy and safety of pediatric phase I oncology trials in the era of dose-intensive chemotherapy and to analyze how efficiently these trials are conducted...
  37. ncbi request reprint Congenital neuroblastoma arising in the deltoid muscle
    Tammy Kang
    Department of Pediatrics, The Children s Hospital of Philadelphia, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Pediatr Hematol Oncol 26:101-3. 2004
    ..Histologic and biologic characteristics were consistent with a favorable-prognosis stage 1 neuroblastoma. Following a complete local excision, the child remains in complete remission 3 years from diagnosis...
  38. ncbi request reprint A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer
    Jeffrey M Skolnik
    Division of Clinical Pharmacology and Therapeutics, Children s Hospital of Philadelphia, Abramson Research Center, Suite 916, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104, USA
    Cancer Chemother Pharmacol 57:458-64. 2006
    ....
  39. doi request reprint Characteristics and outcome of pediatric patients enrolled in phase I oncology trials
    Aerang Kim
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10 CRC, Room 1 3872, Bethesda, MD 20892, USA
    Oncologist 13:679-89. 2008
    ..To describe the characteristics of pediatric subjects who enroll in phase I trials, to determine the associations between pre-enrollment characteristics and the risk for toxicity, and to analyze response and survival outcomes...
  40. doi request reprint Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias
    Robin E Norris
    Division of Clinical Pharmacology and Therapeutics, Children s Hospital of Philadelphia, Abramson Research Center, 3615 Civic Center Blvd, Suite 916, Philadelphia, PA 19104, USA
    Cancer Chemother Pharmacol 65:1125-30. 2010
    ..In this pre-clinical study we evaluated the in vitro activity of both traditional antifols (methotrexate, aminopterin) and novel antifols (pemetrexed, talotrexin) in childhood acute leukemias and lymphomas...
  41. ncbi request reprint Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2
    Brigitte C Widemann
    Pediatric Oncology Branch, Pediatric Oncology Branch, National Cancer Institute, 10 Center Dr, Bldg 10, Rm 13C103, Bethesda, MD 20892 1920, USA
    J Natl Cancer Inst 96:1557-9. 2004
    ..Intrathecal CPDG2 is well tolerated, rapidly decreases CSF methotrexate concentrations, and appears to be efficacious for treating accidental intrathecal methotrexate overdoses...
  42. ncbi request reprint Understanding and managing methotrexate nephrotoxicity
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10 CRC Room 1 5750, Bethesda, Maryland 20892 1101, USA
    Oncologist 11:694-703. 2006
    ..7% (range, 84%-99.5%). The early administration of CPDG(2) in addition to LV may be beneficial for patients with MTX-induced renal dysfunction and significantly elevated plasma MTX concentrations...
  43. ncbi request reprint The bioavailability of oral methotrexate in children with inflammatory bowel disease
    Michael C Stephens
    Center for Pediatric IBD, The Children s Hospital of Philadelphia, Pennsylvania, USA
    J Pediatr Gastroenterol Nutr 40:445-9. 2005
    ..Although no available pharmacologic data support the assumption that the bioavailability of methotrexate is diminished in patients with inflammatory bowel disease, most such patients receive methotrexate parenterally...
  44. ncbi request reprint Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives
    Barry D Anderson
    National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD 20892 7436, USA
    J Clin Oncol 22:4846-50. 2004
    ....
  45. ncbi request reprint Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study
    Susan R Rheingold
    Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Clin Oncol 25:1512-8. 2007
    ..To determine the maximum-tolerated dose, toxicity, pharmacokinetics, and biologic effects of G3139 when administered with doxorubicin and cyclophosphamide to children with relapsed solid tumors...
  46. ncbi request reprint A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 12:4882-7. 2006
    ..To determine the toxicity profile, dose-limiting toxicities, and maximum tolerated dose of ABT-751 administered orally once daily for 7 days, repeated every 21 days...
  47. ncbi request reprint Anticancer effects of fenretinide in human medulloblastoma
    C Damodar Reddy
    Division of Neuro Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Cancer Lett 231:262-9. 2006
    ..These results suggest that pharmacologically achievable concentrations of fenretinide are effective in killing MB cells and thus show its therapeutic potential to treat human MB...
  48. pmc Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892 1101, USA
    J Clin Oncol 28:3979-86. 2010
    ..To assess the role of the recombinant bacterial enzyme, glucarpidase (carboxypeptidase-G(2)), leucovorin, and thymidine in the management and outcome of patients with high-dose methotrexate (HDMTX) -induced nephrotoxicity...
  49. ncbi request reprint A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Clin Cancer Res 13:1789-93. 2007
    ..To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein (Hsp) 90 inhibitor, 17-allylaminogeldanamycin (17-AAG)...
  50. ncbi request reprint A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study
    Mason Bond
    B C Children s Hospital, Vancouver, British Columbia, Canada
    Pediatr Blood Cancer 50:254-8. 2008
    ..A phase II study of imatinib in children and young adults with select solid tumors was performed...
  51. ncbi request reprint A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study
    Anne Marie Langevin
    University of Texas Health Science Center, San Antonio, Texas, USA
    Pediatr Blood Cancer 50:577-80. 2008
    ....
  52. ncbi request reprint The importance of pharmacokinetic limited sampling models for childhood cancer drug development
    J Carl Panetta
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 9:5068-77. 2003
    ....
  53. ncbi request reprint Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Clin Oncol 25:1505-11. 2007
    ..The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic properties of pemetrexed in children...
  54. doi request reprint Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study
    Julia L Glade Bender
    College of Physicians and Surgeons of Columbia University, New York, NY, USA
    J Clin Oncol 26:399-405. 2008
    ..Primary aims included estimating the maximum-tolerated dose (MTD) and determining the dose-limiting toxicities (DLTs), pharmacokinetics, and biologic effects of BV in children with cancer...
  55. ncbi request reprint Testing of new agents in childhood cancer preclinical models: meeting summary
    Peter J Houghton
    St Jude Children s Research Hospital, Memphis, Tennessee 38101, USA
    Clin Cancer Res 8:3646-57. 2002
    ..This report is a synthesis of the workshop's presentations and discussions...
  56. pmc Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study
    Elizabeth A Raetz
    Department of Pediatrics, New York University, School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, New York, NY 10016, USA
    J Clin Oncol 26:3756-62. 2008
    ....
  57. ncbi request reprint Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015)
    Susan M Blaney
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 22:4804-9. 2004
    ..To determine the maximum-tolerated dose, dose-limiting toxicity (DLT), and pharmacodynamics of the proteasome inhibitor bortezomib (formerly PS-341) in children with recurrent or refractory solid tumors...
  58. pmc Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study
    Kristin A Bradley
    University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Neuro Oncol 10:752-8. 2008
    ..The maximum tolerated dose of MGd and the recommended phase II dose was 4.4 mg/kg when administered as a daily intravenous bolus in conjunction with 6 weeks of involved field radiation therapy for pediatric intrinsic pontine gliomas...
  59. ncbi request reprint Propofol pharmacokinetics
    Athena F Zuppa
    Pediatr Crit Care Med 4:124-5. 2003
  60. ncbi request reprint Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, Seattle, WA, USA
    Pediatr Blood Cancer 47:790-4. 2006
    ..The Children's Oncology Group conducted a phase II trial of 21-day continuous infusion topotecan to determine the response rate in pediatric patients with recurrent or refractory malignant solid tumors...
  61. ncbi request reprint The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function
    Athena F Zuppa
    Department of Anesthesia and Critical Care Medicine, Division of Critical Care Medicine, Children s Hospital of Philadelphia, USA
    Crit Care Med 32:2318-22. 2004
    ..To determine the impact of a thyroid hormone infusion (T4) on the vasopressor requirements in children with cessation of neurologic function (i.e., brain death) during evaluation for organ recovery..
  62. pmc A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group
    Kaci L Osenga
    The University of Wisconsin Madison, Madison, Wisconsin, USA
    Clin Cancer Res 12:1750-9. 2006
    ..Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors...
  63. ncbi request reprint Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942)
    Shana S Jacobs
    Children s National Medical Center, Washington, District of Columbia, USA
    Pediatr Blood Cancer 49:250-5. 2007
    ..We performed a pilot study incorporating oral and 24-hr continuous IV infusion (CIVI) TG in children with newly diagnosed standard-risk ALL...
  64. ncbi request reprint Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 24:3678-85. 2006
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the histone deacetylase inhibitor, depsipeptide, in children with refractory or recurrent solid tumors...
  65. ncbi request reprint Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia
    Jeffrey Blumer
    University Hospitals of Cleveland, Cleveland, Ohio, USA
    Pediatr Blood Cancer 49:687-93. 2007
    ..The goals of this phase 1, open-label, uncontrolled study were to assess the pharmacokinetic profile and safety of darbepoetin alfa in pediatric patients with CIA...
  66. ncbi request reprint A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study
    Terzah M Horton
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 13:1516-22. 2007
    ..A phase 1 study to determine the maximum-tolerated dose, dose-limiting toxicity, pharmacokinetics, and biological effects of bortezomib in children with recurrent/refractory leukemia...
  67. ncbi request reprint Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children's Oncology Group report
    Janet L Franklin
    Childrens Hospital Los Angeles, Los Angeles, California, USA
    Pediatr Blood Cancer 50:533-6. 2008
    ..To determine the response rate and toxicity of docetaxel when administered as a 60 mg/m(2) dose by 1 hr intravenous (IV) infusion weekly x 3 weeks in children with relapsed acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML)...
  68. ncbi request reprint Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study
    Lisa R Bomgaars
    Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 25:4622-7. 2007
    ..A phase II study was performed to determine the efficacy of irinotecan (IRN) in children with refractory solid tumors. Secondary objectives were to evaluate toxicity, pharmacokinetics, pharmacodynamics, and UGT1A1 genotype...
  69. ncbi request reprint Case study. All for one, or one for all? Commentary
    Peter C Adamson
    Hastings Cent Rep 37:13-4. 2007
  70. ncbi request reprint Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study
    Najat C Daw
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:6172-80. 2005
    ..Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors...
  71. pmc Recommended changes to oncology clinical trial design: revolution or evolution?
    Mark J Ratain
    University of Chicago, Chicago, IL, USA
    Eur J Cancer 44:8-11. 2008
  72. ncbi request reprint Intrathecal mafosfamide: a preclinical pharmacology and phase I trial
    Susan M Blaney
    Texas Children s Cancer Center, 6621 Fannin St, CC 1410 00, Houston, TX 77030 2399, USA
    J Clin Oncol 23:1555-63. 2005
    ..A phase I and pharmacokinetic study of IT mafosfamide was performed to determine a dose for subsequent phase II trials...
  73. pmc Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:4921-7. 2008
    ..We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors...

Research Grants3

  1. Pediatric Pharmacology Research Unit Network
    Peter Adamson; Fiscal Year: 2004
    ....
  2. Mentored Specialized Clinical Investigator Development Award (MSCIDA)
    Peter Adamson; Fiscal Year: 2006
    ..Lay summary) Infections are a leading cause of serious illness in babies. Dr. Wade will perform research to determine how to optimize the dosing of drugs used to treat infections caused by yeast and the influenza (flu) virus. ..
  3. Children's Oncology Group Phase 1 / Pilot Consortium
    Susan Blaney; Fiscal Year: 2007
    ..Development of targeted therapy for childhood cancer offers the prospect of more efficacious and less toxic therapeutics. ..